Skinvisible, Inc. (SKVI)
OTCMKTS · Delayed Price · Currency is USD
0.3500
-0.1510 (-30.14%)
Nov 3, 2025, 2:56 PM EST
Skinvisible Employees
Skinvisible had 2 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$10,000
Profits / Employee
-$263,633
Market Cap
2.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | 0 | - |
| Dec 31, 2023 | 2 | 0 | - |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | 0 | - |
| Dec 31, 2020 | 2 | -1 | -33.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ESG Inc. | 225 |
| Crimson Wine Group | 203 |
| South Dakota Soybean Processors, LLC | 139 |
| Reed's | 24 |
| Citrine Global | 18 |
| Cordyceps Sunshine Biotech Holdings | 13 |
| Golden Growers Cooperative | 1 |
Skinvisible News
- 6 weeks ago - Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection - Accesswire
- 10 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 10 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 1 year ago - Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development - Accesswire
- 1 year ago - Promising Data on Transdermal Obesity Formulations Announced by Skinvisible - Accesswire
- 1 year ago - Skinvisible Expands Obesity Patent Application for Transdermal Delivery - Accesswire
- 1 year ago - Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome - Accesswire
- 3 years ago - Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug - Accesswire